David Gow has been named president and CEO of the Center for Houston's Future. His role is effective September 3.Photo via CultureMap

A nonprofit organization dedicated to leading Houston into the future has named its next leader.

The Center for Houston’s Future named David Gow as president and CEO, succeeding Brett Perlman, who was announced in April to be remaining at the Center with a focus on the Center’s hydrogen initiative. Gow is the founder and chairman of Gow Media, InnovationMap's parent company. His role is effective September 3.

“I am excited to step into this opportunity with the Center and work with the team, the board and many other stakeholders to help shape Houston’s future,” Gow says in a news release. “The Center presents an exciting opportunity to cast a vision for our region and identify initiatives that will make an impact.”

Gow — whose career includes a portfolio of online media properties and ESPN Radio — is a board member of Goose Capital and chair of MSAI, an entity he formed through a SPAC acquisition. Before he founded Gow Media, he served as CFO and CEO of an online watch retailer, Ashford.com. Prior to Ashford, Gow was director of corporate strategy at Compaq Computers and a consultant at McKinsey & Co. He received his master’s in public policy from Harvard and his bachelor's in economics from Williams College.

“David’s portfolio of experiences and skills, record of innovation and success, and deep commitment to the Houston community make him the perfect fit to lead the Center as we chart and execute on our next set of initiatives focused on ensuring a bright future for all residents in the Houston region,” adds Center for Houston’s Future Board Chair Cindy Yeilding.

In his new role, Gow will lead the Center’s next effort, Vision 2050, which plans to identify the city's key issues, gaps, and opportunities.

“Today’s announcement also reflects the success of the Center’s clean hydrogen program,” Yeilding continues. “On behalf of the Center’s board, I’d also like to recognize Brett for launching and building such a successful and important effort as well as his overall leadership and record of achievement at the Center these past seven years.”

Jim Dillon has been named CEO of BiVACOR. Photo courtesy of BiVACOR

Houston med device company names new CEO

new hire

Houston-based medical device company BiVACOR has brought aboard a new CEO.

Jim Dillon, a longtime executive in the medical device sector, has been hired to lead BiVACOR and join its board of directors. Dillon succeeds former heart surgeon Dr. Thomas Vassiliades, whose appointment as CEO was announced in January 2022.

“Jim’s leadership style, combined with his experience in building high-performance teams as well as expertise in the heart failure field, makes him the ideal person to lead BiVACOR,” Raymond Cohen, chairman of BiVACOR, says in a news release.

Cohen was named chairman of BiVACOR in December 2023.

Most recently, Dillon was CEO of Massachusetts-based BioVentrix, a medical device company that focuses on minimally invasive procedures aimed at preventing heart failure. He previously held sales and marketing positions at medical device companies Abiomed, TherOx, and InfraReDx.

In November, the U.S. Food and Drug Administration (USDA) paved the way for BiVACOR to conduct a first-in-human clinical feasibility study of its Total Artificial Heart product. The study, initially featuring three patients at Houston’s Texas Heart Institute, is set to start during the first half of 2024. It will evaluate the device’s use as a substitute for a heart transplant.

The device “is unique in its complexity and importance as an advanced treatment option for end-stage biventricular heart failure patients,” Dillon says, and promises “to truly revolutionize the field.”

About 100,000 patients suffering from severe heart failure could benefit from BiVACOR’s artificial heart, the company says. For these patients, drug therapy is limited and the health prognosis is bleak, given the scarcity of donor hearts around the world.

Founded in 2008, BiVACOR maintains its headquarters in Houston, along with offices in Huntington Beach, California, and Brisbane, Australia.

To date, BiVACOR has raised nearly $37.8 million, according to CB Insights. The company’s investors include Boston-based Cormorant Asset Management, Australia-based OneVentures, the Australia Department of Health, and the National Institutes of Health (NIH).

SeisWave specializes in cost-effective, cloud-based seismic data processing. Photo via Getty Images

Houston energy startup joins Texas-based climate accelerator

ready to grow

An Austin-based climate accelerator announced its 2023 cohort, which includes a Houston cleantech startup.

StudioX named seven startups to its 2023 cohort, and SeisWave Corp., a seismic service company, will join the program that aims to help the world reach net-zero targets by 2050. The group comprises Studio X's third cohort since the company launched in 2020.

SeisWave specializes in cost-effective, cloud-based seismic data processing.

Other companies in the cohort include:

  • AI Technology & Systems: A NASA iTech company that provides compressed AI models and software
  • Austere Environmental: An environmental remediation solution that extracts chemical contaminants in soil, drill cuttings, and tailings
  • Economical Energy: A long-duration energy storage solution company
  • Flexergy: A developing highly efficient hydrogen gas compression, storage and distribution system
  • Onvol: An IoT power solutions tech company with applications in wind energy, transport, and mining
  • Project Geminae: A Midland, Texas-based AI-powered portfolio optimization platform advancing predictive modeling across industries

The companies will participate in a 16-week program and mentorship through the cohort, along with investment opportunities.

“Our accelerator program helps to close that gap through bringing together an engaged community that grows these companies at a faster rate, ultimately driving innovation, and helping to evolve global energy solutions,” Jeff Allyn, CEO of Studio X, says in a statement.

Studio X is fully-owned and incubated by Shell and aims to "break down the silos of traditional R&D," according to its website. Click here to view some of the accelerator's past participants.

The company will host an Accelerator Showcase Event Friday, Nov. 10, where companies will pitch their concepts and offer a Q&A session. Register here.

Another Shell-backed accelerator announced its cohort earlier this week. In partnership with Greentown Labs, the organizations announced the cohort for Greentown Go Make 2023, which aims to accelerate partnerships between startups and corporations to advance carbon utilization, storage, and traceability solutions. The cohort includes six companies from around the world, from the Netherlands and Canada to Massachusetts and Washington state.

Additionally, The Goodwill Clean Tech Accelerator will launch in Houston next year to help advance clean tech jobs. According to Accenture and Goodwill, which are partners in the accelerator, said it plans to grow the program to 20 cities in the next seven years and train an estimated 7,000 job seekers.

———

This article originally ran on EnergyCapital.

Meet Michelle Accardi, the new CEO of Liongard. Photo courtesy of Liongard

Houston SaaS startup names new CEO

c-suite switchup

A Houston startup founder is transitioning from CEO to make room for a new leader.

Liongard, a software-as-a-service startup with a Managed Service Providers platform, has named Michelle Accardi as CEO, effective April 17. Joe Alapat, co-founder and CEO, will transition to CTO to better lead tech development of the platform, which provides customers with compliance, cybersecurity risk mitigation, and more.

“Now is the right time for Liongard to transform for the long term as we welcome a new member to our executive leadership team,” Alapat says in a news release. “Michelle’s addition will help take Liongard to the next level and accelerate our growth as we address the evolving needs of the industry. This new role allows me to focus on driving Liongard’s innovation forward and helping our MSP partners navigate the modern business landscape.”

Accardi has over 20 years of experience within MSPs and technology companies. She will oversee growth of the company and its product portfolio.

“The Liongard team has accomplished much in its first few years, and that’s a testament to the founding vision and hard work of the entire organization,” Accardi said. “With Liongard in a strong market leadership position, there is a unique opportunity to accelerate growth. Joe and team have built a dynamic company culture and robust technical foundation and I am looking forward to partnering with him to build on the company’s success.”

Most recently as CEO of Logically, Accardi also served as president and chief revenue officer of Star2Star.

“We are excited to welcome Michelle to the team at Liongard,” says Carter Griffin, Liongard board member and general partner at Updata Partners, an investor of Liongard. “We believe that Michelle’s leadership experience and excellent track record will ensure Liongard continues to perform at a very high level.”

Accardi joins the team following a $10 million round of funding that Liongard, which was founded in 2015, secured last year. The startup has raised over $30 million in investment funding to date.

Joe Alapat has transitioned to CTO of Houston-based Liongard. Photo courtesy of Liongard

Houston-based Saranas has tapped a new leader amidst push to commercialize bleed detection technology. Photo via LinkedIn

Houston medical device startup names new CEO

now at the helm

Houston-based medical device company Saranas has tapped a veteran of the healthcare industry as its new CEO.

Mike MacKinnon most recently was president and partner at Madison Ventures +, a private equity firm based in Greenwood Village, Colorado. The firm invests in companies in healthcare, real estate, finance, and other sectors.

Before joining Madison Ventures +, MacKinnon was CEO of Zidan Medical, a startup focused on treatment of airway lesions in patients with early stage lung cancer. He served in that role from 2019 to 2023.

Earlier, he was CEO of ROX Medical, a medical device company specializing in minimally invasive vascular therapy for patients with uncontrolled high blood pressure. He held that role from 2018 to 2019. He previously worked at Philips North America, Volcano, AtheroMed, Hansen Medical, Access Closure, and FoxHollow Technologies.

In a news release, Dan Wolterman, chairman of Saranas’ board and former president and CEO of Memorial Hermann Health System, calls MacKinnon “an accomplished executive with an impressive record of bringing disruptive technology to market, guiding strategy, and driving significant growth.”

Now president and CEO of Nashua, New Hampshire-based medical device company Conformal Medical, James Reinstein was president and CEO of Saranas from 2020 to 2022. Prior to Reinstein, Zaffer Syed held that position from 2017 to 2020. He's still an adviser for the company and recently announced his role as entrepreneur in residence at the Texas Medical Center.

Saranas is working on commercializing its Early Bird Bleed Monitoring System, touted as the first and only system FDA-approved bleeding detection system for procedures involving blood vessels. It is designed to detect bleeds early, enabling physicians to reduce medical risks and potentially avoid costly medical problems.

“Bleeding remains a common issue during and after endovascular procedures and can result in life-threatening complications,” says MacKinnon.

Since being founded in 2013, Saranas has treated over 1,200 patients with its device and has received $29.2 million in funding, according to Crunchbase. This includes a $12.8 million Series B round that Saranas got in 2021 from Chicago-based Baird Capital and Austin-based S3 Ventures.

The Early Bird device was developed at Houston’s Texas Heart Institute. The FDA approved the device in 2019.

Here's what factors a VC will consider when evaluating a startup's leadership, according to Rice University research. Photo via Getty images

Houston research: Why venture capital firms might change a startup's leadership

houston voices

Consider the 21st century's most storied CEOs: Steve Jobs, Bill Gates, Jeff Bezos. All have one thing in common – not only did they run their companies, they founded them.

Each of these corporate leaders, in other words, had to deal with venture capital firms to find critical resources for their firm's success. And it didn't always end well. Jobs was famously fired when Apple's board replaced him with the former CEO of a soft drink company – a disaster from which Apple took years to recover.

Even if changing CEOs doesn't always work out, however, it often does. And when VCs invest heavily in a company, they are proactive in making their investment pay off. Uber founder Travis Kalanick, for example, who cofounded the ride-sharing app Uber, was pressured to step down in 2017 after the company was rocked by scandals that included reported sexual harassment.

Though Kalanick's flameout drew global attention, being swapped out is actually commonplace for CEOs of startups, according to Rice Business Professor Yan "Anthea" Zhang. In a new study coauthored with Salim Chahine of the American University of Beirut, Zhang examined data on 1,156 venture-capital-backed U.S. initial public offerings between 1995 and 2013. Out of this sample, they found that 472 firms, or 40.8 percent, changed CEOs between the first round of venture capital financing and the IPO.

Venture capitalists often have strong reasons for swapping a CEO out, Zhang notes. Guiding a company from its startup phase to the initial public offering requires a huge learning curve. Attention must be paid to human resources, efficiency, public relations – hurdles that can stymie even the most successful startup leaders. Just as in public companies, CEO deficiencies in these areas can harm a company's IPO success and its stock value after the IPO.

A range of other factors, some subtle, lie behind VC decisions to change startup leadership, the researchers found. Distance between the startup and the venture capital firm's headquarters is one such factor. If a New York VC firm funds a company in Nevada, monitoring the day-to-day work of the startup is more difficult and costly than if the venture capital firm is based in California.

A CEO directly appointed by a venture capitalist is more likely to be seen as the venture capital firm's agent, allowing the VC firm to directly control the startup, the researchers write. Overall, VC firms unable to closely monitor the startups they funded were more likely to look for new leadership.

The CEO's past experience, described by the researchers as "human capital," is also pivotal. A CEO who has successfully led a prior IPO is much less likely to be replaced than one who hasn't been through the experience, Zhang's team found. Similarly, a CEO with finance/accounting experience, an MBA, or a graduate level degree is likely to be seen as more credible than one who lacks such experience or degree.

Chaotic as it might seem to swap horses midstream, replacing a CEO for one with more experience and education correlates to a better valuation of the public offering, the researchers found.

These findings are particularly timely now, in the era of COVID-19. As businesses turn to Zoom and other remote techniques, VCs may be questioning more than ever how well they can monitor their investments without frequent site visits and in-person meetings. Building a company has always been a heavy lift. When your funder can only measure your work through a screen, surviving as a startup CEO may be tougher than ever.

------

This article originally ran on Rice Business Wisdom and is based on research from Yan "Anthea" Zhang, the Fayez Sarofim Vanguard Professor of Management – Strategic Management at Jones Graduate School of Business at Rice University.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston Innovation Awards to honor 2 trailblazers with posthumous recognition

top leaders

Last month, the Houston innovation community suffered the loss of two business leaders who left a significant impact on the ecosystem. In November, both individuals' careers will be recognized with Trailblazer Legacy Awards.

Every year, the Houston Innovation Awards honors a Trailblazer Award recipient for their past and future dedication to startups in Houston, and this year InnovationMap is doing approaching the award differently in light of recent events. Paul Frison, founder of the Houston Technology Center, and Scott Gale, executive director of Halliburton Labs, will receive the award posthumously. Frison died on September 5, and Gale died on September 24. The award was decided on by the 2024 judges and InnovationMap.

“I am immensely proud to honor these two remarkable individuals with the Trailblazer Award this year. It is fitting, as they represent two generations of building Houston’s ecosystem," 2023 Trailblazer Award recipient Brad Burke, managing director of the Rice Alliance and the associate vice president for industry and new ventures within Rice University's Office of Innovation, tells InnovationMap.

"Paul Frison was a pioneering leader who helped establish the Houston Technology Center and fostered the city’s tech ecosystem during the initial technology boom around the year 2000. Scott Gale, through his work at Halliburton Labs over the past five years, has been instrumental in launching Houston’s energy transition ecosystem," he continues. "Both have played pivotal roles in championing technology innovators.”

A long-time Houston businessman, Frison founded HTC in 1999 and served as its CEO and president. The organization evolved into Houston Exponential several years ago. Frison remained active within Houston innovation until 2020. Prior to HTC, he served in various executive roles at American Hospital Supply, LifeMark, ComputerCraft, and LifeCell, spending the last 50 of his years in Houston. Born in Glendale, California, he served in the Unites States Coast Guard.

"Houston's vibrant technology entrepreneurship ecosystem is the product of Paul Frison's commitment to innovation, integrity, and growth for our community," says Walter Ulrich, former president and CEO of HTC. "He is the father of Houston's tech ecosystem, CEO of one of Houston's first tech Unicorns, founder of the Houston Technology Center ranked as a top ten technology incubator by Forbes, philanthropist, veteran, and family man."

Gale helped to launch Halliburton Labs in 2020. Prior to that role, he lead global strategy initiatives for Halliburton. A Brigham Young University graduate, he received his MBA from Rice University in 2019, where he co-founded the Jones Student Association for Executives. After his graduation, he served on the the Rice Business Alumni Association Board and the Energy Advisory Board for the Rice Alliance Clean Energy Accelerator. He was also a voice actor and the co-host of two podcasts: Rice University's Owl Have You Know Podcast, which shares experiences of Rice's business community, and the Curiosity podcast, which explored optimism and curiosity with guests and co-host Brad Rossacci.

"We established the Trailblazer Award to recognize the city's innovation leaders, and Scott and Paul both more than deserve to be recognized for their contributions to Houston," Natalie Harms, editor of InnovationMap, says. "My hope is that this year's Trailblazer Legacy Awards pay tribute to their lasting impacts."

The awards will be presented at the November 14 event.

Rice researchers secure $35M federal grant to advance medical device technology

big money

Rice University has secured part of a nearly $35 million federal grant aimed at commercializing a bioelectric implant for treatment of type 2 diabetes and obesity.

The federal Advanced Research Projects Agency for Health awarded the $34.9 million grant to Rice and several other universities.

Rice’s Biotech Launch Pad will lead the effort to commercialize the self-contained, implantable Rx On-site Generation Using Electronics (ROGUE) device. ROGUE houses cells that are engineered to produce type 2 diabetes and obesity therapies in response to patients’ needs.

Carnegie Mellon University leads the team of researchers handling development and testing of ROGUE, which acts as a “living pharmacy” designed to make biologic drugs available on demand in a patient’s body.

The ROGUE initiative aims to keep the cost of this treatment significantly below the cost of other biologics-based treatments.

“ROGUE’s innovative design combines efficient biological manufacturing, long-term durability, and patient-friendly features that have the potential to transform the landscape of biologics delivery,” Omid Veiseh, professor of bioengineering and faculty director of the Rice Biotech Launch Pad, says in a news release.

Paul Wotton, an in-house entrepreneur at the university and executive director of the Rice accelerator, is helping guide ROGUE toward becoming an independent company.

“With the Biotech Launch Pad, our goal is venture creation in parallel to the groundbreaking research at Rice and its collaborating institutions,” Wotton says.

Omid Veiseh is professor of bioengineering and faculty director of the Rice Biotech Launch Pad. Photo courtesy Rice University